Genentech Blasts Eli Lilly's $10M Fee Bid For Dropped IP Suit
Genentech has told a California federal court that it acted in good faith when it accused Eli Lilly of infringing its patent through the sale of a psoriasis drug and therefore...To view the full article, register now.
Already a subscriber? Click here to view full article